These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26400459)

  • 1. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.
    Roy U; Rodríguez J; Barber P; das Neves J; Sarmento B; Nair M
    Nanomedicine (Lond); 2015; 10(24):3597-609. PubMed ID: 26400459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.
    Gao Y; Kraft JC; Yu D; Ho RJY
    Eur J Pharm Biopharm; 2019 May; 138():75-91. PubMed ID: 29678735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of interleukin-2 in patients with HIV infection.
    Pett SL; Kelleher AD; Emery S
    Drugs; 2010 Jun; 70(9):1115-30. PubMed ID: 20518579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano-Medicine as a Newly Emerging Approach to Combat Human Immunodeficiency Virus (HIV).
    Saravanan M; Asmalash T; Gebrekidan A; Gebreegziabiher D; Araya T; Hilekiros H; Barabadi H; Ramanathan K
    Pharm Nanotechnol; 2018; 6(1):17-27. PubMed ID: 29424324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.
    Katusiime C; Ocama P; Kambugu A
    Afr Health Sci; 2014 Sep; 14(3):679-81. PubMed ID: 25352888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of antiretroviral therapy: challenges and needs.
    Moreno S; López Aldeguer J; Arribas JR; Domingo P; Iribarren JA; Ribera E; Rivero A; Pulido F;
    J Antimicrob Chemother; 2010 May; 65(5):827-35. PubMed ID: 20228080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for treatment of latent HIV.
    Barton KM; Burch BD; Soriano-Sarabia N; Margolis DM
    Clin Pharmacol Ther; 2013 Jan; 93(1):46-56. PubMed ID: 23212106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.
    Date AA; Destache CJ
    Biomaterials; 2013 Aug; 34(26):6202-28. PubMed ID: 23726227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limits to potent antiretroviral therapy.
    Telenti A; Paolo Rizzardi G
    Rev Med Virol; 2000; 10(6):385-93. PubMed ID: 11114077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Solving the puzzle" of current HAART: what key strategic trials are needed?
    Carosi G; Torti C
    New Microbiol; 2004 Apr; 27(2 Suppl 1):127-30. PubMed ID: 15646075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV disease and advanced age: an increasing therapeutic challenge.
    Manfredi R
    Drugs Aging; 2002; 19(9):647-69. PubMed ID: 12381235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine applications towards the cure of HIV.
    Lisziewicz J; Tőke ER
    Nanomedicine; 2013 Jan; 9(1):28-38. PubMed ID: 22659241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanochemistry-based immunotherapy for HIV-1.
    Lori F; Calarota SA; Lisziewicz J
    Curr Med Chem; 2007; 14(18):1911-9. PubMed ID: 17691933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].
    Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):543.e1-43. PubMed ID: 25959461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy in the year 2000.
    Tashima KT; Flanigan TP
    Infect Dis Clin North Am; 2000 Dec; 14(4):827-49. PubMed ID: 11144641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?
    Kelly SG; Nyaku AN; Taiwo BO
    Drugs; 2016 Apr; 76(5):523-31. PubMed ID: 26886135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antiretroviral therapy.
    Domingo P; Vidal F
    Expert Opin Pharmacother; 2011 May; 12(7):995-8. PubMed ID: 21434758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.